Literature DB >> 23582318

A therapy for liver failure found in the JNK yard.

Holger Willenbring1, Markus Grompe.   

Abstract

In the liver, the hepatocyte mass is kept stable through a tight balance between hepatocyte death and proliferation that is frequently lost upon acute or chronic liver injury. Wuestefeld et al. (2013) now identify a potentially druggable target that enhances hepatocyte proliferation and promotes liver regeneration, thereby preventing liver failure.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Year:  2013        PMID： 23582318      PMCID： PMC4169283          DOI： 10.1016/j.cell.2013.03.033

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


  7 in total

Review 1.  A liver full of JNK: signaling in regulation of cell function and disease pathogenesis, and clinical approaches.

Authors:  Ekihiro Seki; David A Brenner; Michael Karin
Journal:  Gastroenterology       Date:  2012-06-13       Impact factor: 22.682

2.  TRAIL receptor-mediated JNK activation and Bim phosphorylation critically regulate Fas-mediated liver damage and lethality.

Authors:  Nadia Corazza; Sabine Jakob; Corinne Schaer; Steffen Frese; Adrian Keogh; Deborah Stroka; Daniela Kassahn; Ralph Torgler; Christoph Mueller; Pascal Schneider; Thomas Brunner
Journal:  J Clin Invest       Date:  2006-09       Impact factor: 14.808

Review 3.  The bottleneck of JNK signaling: molecular and functional characteristics of MKK4 and MKK7.

Authors:  Wiebke Haeusgen; Thomas Herdegen; Vicki Waetzig
Journal:  Eur J Cell Biol       Date:  2011-02-18       Impact factor: 4.492

4.  A microRNA-21 surge facilitates rapid cyclin D1 translation and cell cycle progression in mouse liver regeneration.

Authors:  Raymond Ng; Guisheng Song; Garrett R Roll; Niels M Frandsen; Holger Willenbring
Journal:  J Clin Invest       Date:  2012-02-13       Impact factor: 14.808

5.  MKK7 couples stress signalling to G2/M cell-cycle progression and cellular senescence.

Authors:  Teiji Wada; Nicholas Joza; Hai-ying M Cheng; Takehiko Sasaki; Ivona Kozieradzki; Kurt Bachmaier; Toshiaki Katada; Martin Schreiber; Erwin F Wagner; Hiroshi Nishina; Josef M Penninger
Journal:  Nat Cell Biol       Date:  2004-02-22       Impact factor: 28.824

6.  Safety and pharmacokinetics of recombinant human hepatocyte growth factor (rh-HGF) in patients with fulminant hepatitis: a phase I/II clinical trial, following preclinical studies to ensure safety.

Authors:  Akio Ido; Akihiro Moriuchi; Masatsugu Numata; Toshinori Murayama; Satoshi Teramukai; Hiroyuki Marusawa; Naohisa Yamaji; Hitoshi Setoyama; Il-Deok Kim; Tsutomu Chiba; Shuji Higuchi; Masayuki Yokode; Masanori Fukushima; Akira Shimizu; Hirohito Tsubouchi
Journal:  J Transl Med       Date:  2011-05-08       Impact factor: 5.531

7.  Defective liver formation and liver cell apoptosis in mice lacking the stress signaling kinase SEK1/MKK4.

Authors:  H Nishina; C Vaz; P Billia; M Nghiem; T Sasaki; J L De la Pompa; K Furlonger; C Paige; C Hui; K D Fischer; H Kishimoto; T Iwatsubo; T Katada; J R Woodgett; J M Penninger
Journal:  Development       Date:  1999-02       Impact factor: 6.868
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.